Summary

Market Overview
The global cardiac arrhythmia monitoring devices market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).
Cardiac arrhythmia monitoring is a kind of test utilized to determine the cause and type of the irregular heart rates or heart rhythms. The devices utilized to monitor or observe the heart rates are the cardiac arrhythmia monitoring devices. There are numerous products developed for monitoring the heart rhythms including holter monitor, mobile cardiac telemetry or ECG devices.
Market Dynamics
The major factors driving the global cardiac arrhythmia monitoring devices market are the rising demand for smart cardiac monitoring devices owing to increasing incidences of cardiovascular disorders requiring continuous monitoring for better treatment, surging awareness initiatives, advancements in technologies leading to novel product launches.
The increasing development of smart cardiac monitors and rising demand for telecardiology are expected to drive the market’s growth.
The cardiac arrhythmia monitoring devices market is driven by increasing demand of telecardiology, rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of chronic cardiovascular diseases and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.
The cardiac arrhythmia monitoring devices are used widely for continuous monitoring of rhythms of heart for management of the condition properly. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce more developed products such as smart cardiac monitors or smart watches for monitoring. The market for these cardiac arrhythmia monitoring devices is increasing worldwide due to the enhanced number of people suffering from cardiovascular disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market’s growth.
Various novel product launches, research studies, and rising awareness initiatives related to these cardiac arrhythmia monitoring devices contribute to the market’s growth. For instance, in May 24, 2021, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced two novel 510(k) clearances. One for a novel flagship monitors with better design and second for an improved artificial intelligence (AI) capabilities. The novel Zio monitor is developed to enhance patient comfort while its AI capabilities advancements will further improve beat and rhythm diagnostic accuracy.
Uncertain reimbursement policies are expected to hamper the market’s growth.
However uncertain reimbursement policies associated with these cardiac monitoring devices is the key factor which may hamper the market growth. Due to the uncertainty clinicians as well as patients hesitate in adopting these monitoring devices.
The strict rules and regulations for the approval of these devices utilized for monitoring of cardiovascular disorders or conditions is also a factor hindering the growth of the cardiac arrhythmia monitoring devices market. High costs of highly advanced monitors such as smart cardiac monitors or smart watches can also limit the growth of the market.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The cardiac arrhythmia monitoring devices market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, July 22, 2022, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced about receiving clearance for Zio Watch’s ZEUS System (Zio ECG Utilization Software) by USFDA. This system is developed in partnership with Verily, a precision health company. ZEUS System combines trusted cardiac arrhythmia service with deep learned algorithms.
Segment Analysis
The holter monitors segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The holter monitor segment is the highest market holder in the global cardiac arrhythmia monitoring devices market. The global cardiac arrhythmia monitoring devices market is segmented based on product as holter monitors, ECG devices, mobile cardiac telemetry, cardiac event monitors, implantable loop recorders, patch monitor, pacemaker, cardioverter-defibrillator. The holter monitors segment is the largest market shareholder due to the increasing adoption of these devices globally for monitoring, increasing technological advancements and novel product launches.
Holter monitors are the small and wearable device that records the rhythm of heart. It is utilized to determine or detect irregular heartbeats (arrhythmias) risk. Holter monitors test is usually done if a traditional electrocardiogram is unable to provide sufficient details about the condition of the heart. These monitors can spot irregular heart rhythms that may be missed by ECG. Holter monitoring is non-invasive and painless. The monitor is usually worn for 1 to 2 days in which all the heartbeats are recorded by the device. The sensors and the wires are easy to hide under clothing. The device can be attached to a strap or worn on a belt.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market’s growth. For instance, in January 26, 2022, Royal Philips, a health technology company announced about introducing the first at-home, full-service, 12-lead electrocardiogram (ECG) solution that can be utilized in decentralized clinical trials. This clinical-grade solution is the highly advanced patient-centric ECG included within the cardiac monitoring portfolio of Philips, site-based ECGs with leading cloud-based data collection and evaluation services of Philips.
Geographical Analysis
North America holds the largest market share in the global cardiac arrhythmia monitoring devices market.
North America dominates the global cardiac arrhythmia monitoring devices market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of cardiac arrhythmia monitoring devices such as pacemaker, event monitors, ECG devices or holter monitors, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the cardiac arrhythmia monitoring devices market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in February 10, 2021, CardiacSense, a digital health company involved in developing a medical grade watch announced about receiving the CE Mark for its medical grade smart watch device’s marketing & sales in the European Union. The certified indications include Heart Rate Variability (HRV) monitoring and detection of Atrial Fibrillation (A-Fib) with spot Electrocardiogram (ECG) and continuous Photoplethysmography (PPG).
Competitive Landscape
The cardiac arrhythmia monitoring devices market is moderately competitive with local and global companies’ presence. Philips Healthcare, GE Healthcare, Medtronic PLC, Cardiac Sense, BIOTRONIK, iRhythm Technologies, Inc., Preventice Solutions (Boston Scientific Corporation), Medi-Lynx Cardiac Monitoring, LLC., ACS Diagnostics, Abbott and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in January 21, 2021, Boston Scientific announced about entering into a definitive acquisition agreement with Preventice Solutions, Inc., a company offering a whole portfolio of mobile cardiac health solutions and services, including ambulatory cardiac monitors such as long and short-term Holter monitor, mobile cardiac telemetry and cardiac event monitors.
GE Healthcare
Overview: GE Healthcare is a subsidiary of American multinational conglomerate General Electric Company. The company manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures.
Product Portfolio:
CARESCAPE B850 monitor: It incorporates technologically advanced features including smart lead fail and four lead arrhythmia analysis facilitated by EK-Pro algorithm of GE Healthcare. The monitor also provide a broad range of basic or advanced clinical parameters such as regional oximetry (rSO2), plethysmography variability index (PVI), Perfusion Index (PI) and total hemoglobin (SpHb).
Key Development: In July 16, 2022, GE Healthcare announced about introducing portrait mobile continuous wireless wearable sensors patient monitoring solution for supporting clinicians in detecting early patient deterioration.
The global cardiac arrhythmia monitoring devices market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

ページTOPに戻る

Table of Contents